Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H10O7.2H2O |
| Molecular Weight | 338.2663 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3
InChI
InChIKey=GMGIWEZSKCNYSW-UHFFFAOYSA-N
InChI=1S/C15H10O7.2H2O/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6;;/h1-5,16-19,21H;2*1H2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H10O7 |
| Molecular Weight | 302.2357 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Quercetin is a unique bioflavonoid that has been extensively studied by researchers over the past 30 years. Quercetin, the most abundant of the flavonoids (the name comes from the Latin –quercetum, meaning oak forest, quercus oak) consists of 3 rings and 5 hydroxyl groups. Quercetin is a member of the class of flavonoids called flavonoles and forms the backbone for many other flavonoids including the citrus flavonoids like rutin, hesperidins, Naringenin and tangeritin. It is widely distributed in the plant kingdom in rinds and barks. The best described property of Quercetin is its ability to act as antioxidant. Quercetin seems to be the most powerful flavonoids for protecting the body against reactive oxygen species, produced during the normal oxygen metabolism or are induced by exogenous damage [9, 10]. One of the most important mechanisms and the sequence of events by which free radicals interfere with the cellular functions seem to be the lipid peroxidation leading eventually the cell death. To protect this cellular death to happen from reactive oxygen species, living organisms have developed antioxidant line of defense systems [11]. These include enzymatic and non-enzymatic antioxidants that keep in check ROS/RNS level and repair oxidative cellular damage. The major enzymes, constituting the first line of defence, directly involved in the neutralization of ROS/RNS are: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) The second line of defence is represented by radical scavenging antioxidants such as vitamin C, vitamin A and plant phytochemicals including quercetin that inhibit the oxidation chain initiation and prevent chain propagation. This may also include the termination of a chain by the reaction of two radicals. The repair and de novo enzymes act as the third line of defence by repairing damage and reconstituting membranes. These include lipases, proteases, DNA repair enzymes and transferases. Quercetin is a specific quinone reductase 2 (QR2) inhibitor, an enzyme (along with the human QR1 homolog) which catalyzes metabolism of toxic quinolines. Inhibition of QR2 in plasmodium may potentially cause lethal oxidative stress. The inhibition of antioxidant activity in plasmodium may contribute to killing the malaria causing parasites.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26512639
Curator's Comment: There is limited ability of the reviewed flavonoids to access the brain
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28528183 |
|||
Target ID: GO:0072593 |
|||
Target ID: CHEMBL4528 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28433637 |
|||
Target ID: CHEMBL1973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28273864 |
14.29 nM [IC50] | ||
Target ID: Phospholipase A2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28256049 |
1.36 µM [IC50] | ||
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17724002 |
113.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
500 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9816216/ |
630 mg/m² single, intravenous dose: 630 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
QUERCETIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2077 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9816216/ |
630 mg/m² single, intravenous dose: 630 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
QUERCETIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
47 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9816216/ |
630 mg/m² single, intravenous dose: 630 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
QUERCETIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| moderate [IC50 11.6 uM] | ||||
| moderate to strong [IC50 5.5 uM] | ||||
| modest [Ki 10.1 uM] | ||||
| no | ||||
| not significant [IC50 104 uM] | ||||
| not significant [IC50 151 uM] | no (pharmacogenomic study) Comment: drug inhibits caffeine metabolism, which is unrelated to CYP1A2*1C and *1F gene polymorphisms (https://www.hindawi.com/journals/bmri/2014/405071/) |
|||
| potent [IC50 0.65 uM] | ||||
| yes [IC50 15.9 uM] | weak (co-administration study) Comment: AUC increase of 24%, Cmax increase of 31% |
|||
| yes [IC50 4.22 uM] | yes (co-administration study) Comment: 1.8-fold increase in AUC8h and 1.5 fold increase in Cmax |
|||
| yes [IC50 8 uM] | ||||
| yes [IC50 8.1 uM] | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | no (co-administration study) Comment: 133% induction at 50 uM of drug; see https://www.sciencedirect.com/science/article/pii/S1818087618305154#bib0013 for in vivo study |
|||
Page: 5.0 |
yes | weak (co-administration study) Comment: decreased enzyme activity by 10.4% Page: 5.0 |
||
Page: 1.0 |
yes | weak (co-administration study) Comment: increased enzyme activity by 25.3% Page: 1.0 |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Structural damage to proteins caused by free radicals: asessment, protection by antioxidants, and influence of protein binding. | 2001-05-15 |
|
| Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. | 2001-05-15 |
|
| Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. | 2001-05-04 |
|
| Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. | 2001-05 |
|
| Fast repair of the radical cations of dCMP and poly C by quercetin and rutin. | 2001-05 |
|
| Induction of stress response proteins and experimental renal ischemia/reperfusion. | 2001-05 |
|
| Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. | 2001-05 |
|
| Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. | 2001-05 |
|
| PI3K inhibitors reverse the suppressive actions of insulin on CYP2E1 expression by activating stress-response pathways in primary rat hepatocytes. | 2001-05 |
|
| Identification of quercetin glucuronides in human plasma by high-performance liquid chromatography-tandem mass spectrometry. | 2001-04-05 |
|
| Hydroxylations and methylations of quercetin, fisetin, and catechin by Streptomyces griseus. | 2001-04 |
|
| Constituents of Afzelia bella stem bark. | 2001-04 |
|
| Kaempferide triglycoside: a possible factor of resistance of carnation (Dianthus caryophyllus) to Fusarium oxysporum f. sp. dianthi. | 2001-04 |
|
| Evaluation of polyphenolic and flavonoid compounds in honeybee-collected pollen produced in Spain. | 2001-04 |
|
| Measurement of copper-binding sites on low density lipoprotein. | 2001-04 |
|
| Structure-activity study on the quinone/quinone methide chemistry of flavonoids. | 2001-04 |
|
| Natural therapies for ocular disorders, part two: cataracts and glaucoma. | 2001-04 |
|
| Effect of five flavonoid compounds isolated from Quercus dentata Thunb on superoxide generation in human neutrophils and phosphorylation of neutrophil proteins. | 2001-04 |
|
| Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. | 2001-04 |
|
| Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001-04 |
|
| Detection of drug-induced, superoxide-mediated cell damage and its prevention by antioxidants. | 2001-03-15 |
|
| Protective effect of various antioxidants on the toxicity of sulphur mustard administered to mice by inhalation or percutaneous routes. | 2001-03-14 |
|
| Bioactive chemical constituents from Alchornea laxiflora (benth) pax and hoffman. | 2001-03-03 |
|
| Determination of phenolic acids and flavonoids of apple and pear by high-performance liquid chromatography. | 2001-03-02 |
|
| Effects of simple aromatic compounds and flavonoids on Ca2+ fluxes in rat pituitary GH(4)C(1) cells. | 2001-03-02 |
|
| Noni plant may help TB. | 2001-03 |
|
| Presence of aldose reductase inhibitors in tea leaves. | 2001-03 |
|
| Enhanced antioxidant activity after chlorination of quercetin by hypochlorous acid. | 2001-03 |
|
| Flavonoids and phenylpropanoid derivatives from Campanula barbata. | 2001-03 |
|
| Treatment of interstitial cystitis with a quercetin supplement. | 2001-03 |
|
| Chemoprotective potentials of homoisoflavonoids and chalcones of Dracaena cinnabari: modulations of drug-metabolizing enzymes and antioxidant activity. | 2001-03 |
|
| Addition of milk does not affect the absorption of flavonols from tea in man. | 2001-03 |
|
| Flavonoid characters contributing to the taxonomic revision of the Hebe parviflora complex. | 2001-03 |
|
| Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. | 2001-03 |
|
| Relationship between effects of phenolic compounds on the generation of free radicals from lactoperoxidase-catalyzed oxidation of NAD(P)H or GSH and their DPPH scavenging ability. | 2001-03 |
|
| Simultaneous determination of quercetin, kaempferol and (E)-cinnamic acid in vegetative organs of Schisandra chinensis Baill. by HPLC. | 2001-03 |
|
| Reduction of dehydroascorbic acid by homocysteine. | 2001-02-16 |
|
| Separation of kaempferols in Impatients balsamina flowers by capillary electrophoresis with electrochemical detection. | 2001-02-16 |
|
| Pharmacological interventions of cyanide-induced cytotoxicity and DNA damage in isolated rat thymocytes and their protective efficacy in vivo. | 2001-02-03 |
|
| Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. | 2001-02-03 |
|
| Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. | 2001-02 |
|
| A malonylated anthocyanin and flavonols in blue Meconopsis flowers. | 2001-02 |
|
| Guaiane dimers from Xylopia vielana. | 2001-02 |
|
| Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. | 2001-02 |
|
| Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. | 2001-01-30 |
|
| Interaction of sheep liver cytosolic aldehyde dehydrogenase with quercetin, resveratrol and diethylstilbestrol. | 2001-01-30 |
|
| [Polyphenol compounds from Hamamelis virginiana L]. | 2001-01 |
|
| Influence of quercetin on B16 melanotic melanoma growth in C57BL/6 mice and on activity of some acid hydrolases in melanoma tissue. | 2001 |
|
| Protective effect of phenolic compounds isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death. | 2001 |
|
| Electrospray ionisation mass spectrometric study of degradation products of quercetin, quercetin-3-glucoside and quercetin-3-rhamnoglucoside, produced by in vitro fermentation with human faecal flora. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01708278
COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week
Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin
Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin
Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28079005
DCs, exposed to 25uM quercetin, activate a pattern of genes that increase extracellular iron export, resulting in an overall decrease in the intracellular iron content and consequent diminished inflammatory abilities.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:14 GMT 2025
by
admin
on
Mon Mar 31 18:22:14 GMT 2025
|
| Record UNII |
53B03V78A6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C306
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Quercetin dihydrate
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
m9420
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
6151-25-3
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
C75768
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
5284452
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
100000125904
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
53B03V78A6
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
DTXSID9021219
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY | |||
|
SUB32931
Created by
admin on Mon Mar 31 18:22:14 GMT 2025 , Edited by admin on Mon Mar 31 18:22:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |